Role of GPR30 in endometrial pathology after tamoxifen for breast cancer

American Journal of Obstetrics and Gynecology

Volumn 203, Issue 6, 2010, Pages 595.e9-595.e16

  Ignatov, Tanja ^a   Eggemann, Holm ^a   Semczuk, Andrzej ^b   Smith, Bobbie ^a   Bischoff, Joachim ^a   Roessner, Albert ^a   Costa, Serban D ^a   Kalinski, Thomas ^a   Ignatov, Atanas ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Estrogen; GPR30; Tamoxifen

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; G PROTEIN COUPLED RECEPTOR 30; MITOGEN ACTIVATED PROTEIN KINASE; TAMOXIFEN; G PROTEIN COUPLED RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; CANCER CELL; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG INDUCED DISEASE; ENDOMETRIAL DISEASE; ENDOMETRIUM CELL; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; VAGINA BLEEDING; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; ENDOMETRIUM TUMOR; METABOLISM; PATHOLOGY; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; TUMOR CELL CULTURE;

BREAST NEOPLASMS; CELL PROLIFERATION; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; RECEPTORS, G-PROTEIN-COUPLED; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 79952119039     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2010.07.034     Document Type: Article

References (30)

1. Hall JM, Couse JF, Korach KS. The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem 2001;276: 36869-72.
2. Beato M, Klug J. Steroid hormone receptors: an update. Hum Reprod Update 2000;6: 225-36. (Pubitemid 30348891)
3. Improta-Brears T, Whorton AR, Codazzi F, York JD, Meyer T, McDonnell DP. Estrogeninduced activation of mitogen-activated protein kinase requires mobilization of intracellular calcium. Proc Natl Acad Sci U S A 1999;96: 4686-91. (Pubitemid 29190397)
4. Revelli A, Massobrio M, Tesarik J. Nongenomic actions of steroid hormones in reproductive tissues. Endocr Rev 1998;19:3-17. (Pubitemid 29122072)
5. Rae JM, Johnson MD. What does an orphan G-protein-coupled receptor have to do with estrogen? Breast Cancer Res 2005;7:243-4. (Pubitemid 41830160)
6. Prossnitz ER, Oprea TI, Sklar LA, Arterburn JB. The ins and outs of GPR30: a transmembrane estrogen receptor. J Steroid Biochem Mol Biol 2008;109:350-3.
7. Lonning PE, Knappskog S, Staalesen V, Chrisanthar R, Lillehaug JR. Breast cancer prognostication and prediction in the postgenomic era. Ann Oncol 2007;18:1293-306. (Pubitemid 47305001)
8. Shang Y. Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis. Nat Rev Cancer 2006;6:360-8.
9. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998;90:1371-88. (Pubitemid 28439961)
10. Ismail SM. Pathology of endometrium treated with tamoxifen. J Clin Pathol 1994; 47:827-33.
11. Van Leeuwen FE, Benraadt J, Coebergh JW, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994;343:448-52. (Pubitemid 24059587)
12. Prossnitz ER, Arterburn JB, Smith HO, Oprea TI, Sklar LA, Hathaway HJ. Estrogen signaling through the transmembrane G proteincoupled receptor GPR30. Annu Rev Physiol 2008;70:165-90. (Pubitemid 351738176)
13. Filardo EJ. Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer. J Steriod Biochem Mol Biol 2002;80:231-8. (Pubitemid 34233742)
14. Vivacqua A, Bonofiglio D, Recchia AG, et al. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 7betaestradiol and hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol 2006;20:631-46. (Pubitemid 43291214)
15. Ignatov A, Ignatov T, Roessner A, Costa SD, Kalinski T. Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells. Breast Cancer Res Treat 2010; 123:87-96.
16. Lin BC, Suza Wa M, Blind RD, et al. Stimulating the GPR30 estrogen receptor with a novel tamoxifen analogue activates SF-1 and promotes endometrial cell proliferation. Cancer Res 2009;69:5415-23.
17. Smith HO, Leslie KK, Singh M, et al. GPR30: a novel indicator of poor survival for endometrial carcinoma. Am J Obstet Gynecol 2007;196:386-9.
18. Ignatov A, Lintzel J, Kreienkamp HJ, Schaller HC. Sphingosine-1-phosphate is a high-affinity ligand for the G protein-coupled receptor GPR6 from mouse and induces intracellular CA2+ release by activating the phingosine- kinase pathway. Biochem Biophys Res Commun 2003;311:329-36. (Pubitemid 37340081)
19. Ignatov A, Robert J, Gregory-Evans C, Schaller HC. RANTES stimulates CA2+ mobilization and inositol trisphosphate (IP3) formation in cells transfected with G proteincoupled receptor 75. Br J Pharmacol 2006; 149:490-7. (Pubitemid 44658509)
20. Ignatov A, Bischoff J, Ignatov T, et al. APC promoter hypermethylation is an early event in endometrial tumorigenesis. Cancer Sci 2010; 101:321-7.
21. Filardo EJ, Graeber CT, Quinn JA, et al. Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast can cer and its association with clinicopathologic determinants of tumor progression. Clin Cancer Res 2006;12:6359-66. (Pubitemid 44799705)
22. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on ecurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365: 1687-717.
23. Fornander T, Rutqvist LE, Cedermark B, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989;1:117-20 (Pubitemid 19034031)
24. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 2005;307:1625-30. (Pubitemid 40354745)
25. Thomas P, Pang Y, Filardo EJ, Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 2005;146:624-32. (Pubitemid 40129818)
26. Lonning PE, Johannessen DC, Lien EA, Ekse D, Fotsis T, Adlercreutz H. Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients. J teroid Biochem Mol Biol 1995;52:491-6.
27. Sunderland MC, Osborne CK. Tamoxifen in premenopausal patients with metastatic breast cancer: a review. J Clin Oncol 1991;9:1283-97.
28. Cheng WF, Lin HH, Torng PL, Huang SC. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients. Gynecol Oncol 1997;66: 233-7.
29. Swerdlow AJ, Jones ME. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J Natl Cancer Inst 2005;97:375-84. (Pubitemid 40425956)
30. LeBlanc K, Sexton E, Parent S, et al. Effects of 4-hydroxytamoxifen, raloxifene and ICI 182 780 on survival of uterine cancer cell lines in the presence and absence of exogenous estrogens. Int J Oncol 2007;30:477-87.